Abstract 1567P
Background
The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) and dipeptidyl peptidase-4 inhibitors (DPP4I) on the risk of gastric cancer remains unknown. This study aims to compare the effects of SGLT2I and DPP4I on gastric cancer and other gastric diseases.
Methods
This was a retrospective population-based cohort study of patients with type-2 diabetes mellitus (T2DM) on either SGLT2I or DPP4I between 1st January 2015 and 31st December 2020 in Hong Kong. The primary outcome was new-onset gastric cancer, peptic ulcer (PU), acute gastritis, non-acute gastritis, and gastroesophageal reflux disease (GERD). Propensity score matching (1:1 ratio) using the nearest neighbour search was performed. Univariable and multivariable Cox regression was applied to identify the associations.
Results
This cohort included 62858 T2DM patients (median age: 62.2 years old [SD: 12.8]; 55.93% males). 23442 patients used SGLT2I, and 39416 patients used DPP4I. After matching, the incidence of gastric cancer (incidence rate ratio, IRR: 0.26; 95% confidence interval, CI: 0.18-0.37) was significantly lower in SGLT2I users than in DPP4I. SGLT2I was associated with lower risks of gastric cancer (Hazard ratio, HR: 0.30; 95% CI: 0.19-0.48). SGLT2I was also associated with lower risks of PU (HR: 0.66; 95% CI: 0.47-0.91), acute gastritis (HR: 0.31; 95% CI: 0.20-0.48), non-acute gastritis (HR: 0.35; 95% CI: 0.25-0.49), and GERD (HR: 0.62; 95% CI: 0.50-0.76) compared to DPP4I after adjustments. In the subgroup analysis, the results remained consistent across different age groups and genders. SGLT2I was associated with lower risks of gastric cancer amongst patients without prior H. pylori infection (HR: 0.26; 95% CI: 0.18-0.37) but not those with prior infection (HR: 0.28; 95% CI: 0.08-1.01). The results were consistent in the competing risk models and the different matching approaches in the sensitivity analysis.
Conclusions
SGLT2I was associated with lower risks of new-onset gastric cancer than DPP4I. SGLT2I was also associated with lower risks of PU, acute gastritis, non-acute gastritis, and GERD after matching and adjustments compared to DPP4I.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Cardiovascular Analytics Group.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1521P - Addition of durvalumab to CROSS in oesophageal adenocarcinoma is feasible and safe
Presenter: Hans Schloesser
Session: Poster session 21
1523P - Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)
Presenter: Mustapha Tehfe
Session: Poster session 21
1524P - First-line TST001 plus capecitabine and oxaliplatin (CAPOX) for advanced G/GEJ cancer with CLDN18.2 positive overall survival data from study transtar102-Cohort C
Presenter: Lin Shen
Session: Poster session 21
1526P - Phase Ib results of bemarituzumab (BEMA)+mfolfox6+nivolumab (NIVO) for advanced gastric/gastroesophageal junction cancer (G/GEJC): Fortitude-102 part 1
Presenter: Zev Wainberg
Session: Poster session 21
1527P - Efficacy and safety of infigratinib in locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with FGFR2 gene amplification
Presenter: Jiajia Yuan
Session: Poster session 21
1528P - A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
Presenter: Daniel Olson
Session: Poster session 21
1529P - Tislelizumab plus chemotherapy sequential neo-chemoradiotherapy therapy as total neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma (ETNT)
Presenter: Wenwu He
Session: Poster session 21
1530P - Health-related quality of life (hrqol) in patients with claudin-18 isoform 2-positive (CLDN18.2+) locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma: Results from SPOTLIGHT and GLOW
Presenter: Florian Lordick
Session: Poster session 21